Budesonide suppository - Dr Falk Pharma

Drug Profile

Budesonide suppository - Dr Falk Pharma

Latest Information Update: 02 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Falk Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ulcerative proctitis

Most Recent Events

  • 16 Feb 2017 Phase-III clinical trials in Ulcerative proctitis in Slovakia (Rectal) (EudraCT2016-001921-15)
  • 15 Oct 2016 Safety and efficacy results from the phase II trial in Ulcerative proctitis presented at the 24th United European Gastroenterology Week
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top